









Markets
/
Stocks
/
nasdaq-kod
/

Kodiak Sciences Inc

KOD



View Detailed Chart

31.080USD

+3.630+13.22%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

1.65BMarket Cap

LossP/E TTM



Kodiak Sciences Inc

31.080

+3.630+13.22%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+13.22%

5 Days

+15.24%

1 Month

+42.11%

6 Months

+760.94%

Year to Date

+212.36%

1 Year

+214.89%

View Detailed Chart

TradingKey Stock Score of Kodiak Sciences Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kodiak Sciences Inc's Score

Industry at a Glance

Industry Ranking

228 / 501

Overall Ranking

404 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

21.286

Target Price

-18.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kodiak Sciences Inc Highlights

StrengthsRisks

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Undervalued

The company’s latest PE is -4.97, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.90M shares, decreasing 17.74% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 764.14K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.